Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07607925 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
A Phase 1 study, sponsored by GlaxoSmithKline.
- Not yet
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT07607925 is a Phase 1 study that has not yet begun recruiting, run by GlaxoSmithKline. The registered enrollment target is 49 participants.
The verdict
NCT07607925, a Phase 1 study, has not yet begun recruiting, sponsored by GlaxoSmithKline.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.
Interventions
- DRUG GSK5926371
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2026-06-12 |
| Est. Completion | 2029-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07607925
The ClinicalTrials.gov registry entry for NCT07607925 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK5926371 is the first listed.
NCT07607925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07607925 about?
NCT07607925 is a clinical study titled "A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL". The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seek...
What is the current status of trial NCT07607925?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2026-06-12. Estimated completion is 2029-09-24.
What interventions are being tested in trial NCT07607925?
The interventions under investigation include: GSK5926371 (DRUG).
Who is sponsoring clinical trial NCT07607925?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.